Yan Leyfman/LinkedIn
Apr 14, 2026, 13:09
Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn:
”Thank you to Cancer Network for the feature.
Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease
Gene editing has moved from concept to clinic.
By leveraging CRISPR to reactivate fetal hemoglobin, we’re no longer just managing Sickle Cell Disease – we’re aiming to rewrite its biology.
Targeting regulators like BCL11A is elegant.
Making it durable, scalable, and accessible is the real challenge.
This is where curative intent becomes tangible.
Worth the read if you’re following where ‘hematology and gene therapy’ is heading.”
Stay updated with Hemostasis Today.
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day